source
- Hansoh says China’s biopharma is shifting from follower to frontrunner, now behind 30% of investigational drugsHansoh Pharmaceutical used its first‑half earnings release to claim that China’s innovative biopharma sector is moving from a follower role to a frontrunner position. The company highlighted that…
- Spyre Therapeutics cuts rheumatoid arthritis program after weak Phase 2 TL1A antibody resultsSpyre Therapeutics reported that its Phase 2 study of the anti‑TL1A antibody SPY072 in rheumatoid arthritis did not meet the efficacy expectations set earlier this year. The company said the data f…